Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8830136 | 0.84 | TYR (0.43) | KDM4EALDH1A1RECQLTYRHSP90AA1 | |
| SCHEMBL2266518 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1ERN1PTPN1CES2 | |
| SCHEMBL16953682 | 0.80 | RECQL (0.40) | RECQLCES2CES1EIF4A3 | |
| SCHEMBL16959712 | 0.80 | RECQL (0.36) | RECQLCES2CES1EIF4A3 | |
| SCHEMBL23244733 | 0.79 | ERN1 (0.39) | KDM4EALDH1A1ERN1PTPN1CES2 | |
| SCHEMBL10338935 | 0.78 | LMNA (0.50) | KDM4EALDH1A1TYRERN1 | |
| SCHEMBL605235 | 0.78 | TYR (0.58) | KDM4EALDH1A1TYRHSP90AA1HSP90AB1 | |
| SCHEMBL29724084 | 0.78 | LMNA (0.50) | KDM4EALDH1A1TYRERN1 | |
| SCHEMBL29818656 | 0.78 | TYR (0.48) | KDM4EALDH1A1TYRHSP90AA1HSP90AB1 | |
| SCHEMBL3117644 | 0.78 | TYR (0.48) | KDM4EALDH1A1TYRHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | TYR, APC, TP53 | KDM4E 1550/4885ALDH1A1 3494/4885RECQL 4617/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | KDM4E 3041/4885ALDH1A1 3257/4885RECQL 1259/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | KDM4E 2526/4885ALDH1A1 2358/4885RECQL 1279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.